natgillin/translations-raw huggingface dataset:
Administration of prothrombin complex concentrates (PCCs) or recombinant factor VIIa may also be considered. 
Razmisliti je treba tudi o uporabi koncentratov protrombinskih kompleksov (PCCs - Prothrombin complex concentrates) ali rekombinantnega faktorja VIIa.
In the absence of other criteria for dose reduction (age, body weight), no dose adjustment is necessary (see section 5.2). 
V odsotnosti drugih meril za zmanjšanje odmerka (starost, telesna masa) prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
Blood clots may break off and travel to the brain and lead to a stroke or to other organs and prevent normal blood flow to that organ (also known as a systemic embolism). 
Krvni strdki se lahko odtrgajo in zaidejo v možgane, kar lahko vodi do možganske kapi, ali pa v druge organe in tako preprečijo normalen pretok krvi skozi organ (kar se imenuje tudi sistemska embolija).
The results across phase I studies showed no discernible difference in apixaban pharmacokinetics between White/Caucasian, Asian and Black/African American subjects. 
Rezultati študij I. faze ne kažejo očitnih razlik v farmakokinetiki apiksabana med belci, Azijci in črnci/Afroameričani.
Prevention of recurrent DVT and/or PE following completion of 6 months of treatment for DVT or PE 
Preprečevanje ponovne GVT in/ali PE po koncu 6-mesečnega zdravljenja GVT ali PE
In patients undergoing knee replacement surgery The recommended duration of treatment is 10 to 14 days. 
Bolniki po kirurški zamenjavi kolena Priporočeno trajanje zdravljenja je od 10 do 14 dni.
Apixaban has a total clearance of about 3.3 L/h and a half-life of approximately 12 hours. 
Skupni očistek apiksabana znaša približno 3,3 l/h, razpolovni čas pa približno 12 ur.
Table 4: Efficacy Results from Pivotal Phase III Studies Study 
Preglednica 4: Rezultati učinkovitosti iz ključnih študij III. faze Študija
Crushed Eliquis tablets are stable in water, D5W, apple juice, and apple puree for up to 4 hours. 
Zdrobljene tablete zdravila Eliquis so stabilne v vodi, D5W, jabolčnem soku in jabolčni čežani do 4 ure.
Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g., numbness or weakness of the legs, bowel or bladder dysfunction). 
Bolnike je treba pogosto nadzirati glede pojava znakov in simptomov nevrološke okvare (npr. odrevenelost ali oslabelost nog ali motnje delovanja črevesja ali sečnega mehurja).
Information for healthcare professionals 
Informacije za zdravstvenedelavce
Patients undergoing cardioversion Apixaban can be initiated or continued in NVAF patients who may require cardioversion. 
Zdravljenje z apiksabanom lahko uvedemo ali nadaljujemo pri bolnikih z NVAF, ki bi lahko potrebovali kardioverzijo.
NVAF - No dose adjustment required, unless criteria for dose reduction are met (see Dose reduction at the beginning of section 4.2). 
NVAF - prilagajanje odmerka ni potrebno, razen če so izpolnjena merila za zmanjšanje odmerka (glejte Zmanjšanje odmerka na začetku poglavja 4.2).
Therefore, the use of Eliquis is not recommended in this setting. 
Zato uporaba zdravila Eliquis v takem primeru ni priporočljiva.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially "sodiumfree". 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na tableto, kar v bistvu pomeni ''brez natrija''.
The safety and efficacy of Eliquis in children and adolescents below age 18 have not been established. 
Varnost in učinkovitost zdravila Eliquis pri otrocih in mladostnikih, mlajših od 18 let, nista bili dokazani.
The European Medicines Agency has deferred the obligation to submit the results of studies with Eliquis in one or more subsets of the paediatric population in venous and arterial embolism and thrombosis (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Eliquis za eno ali več skupin pediatrične populacije pri venski in arterijski emboliji in trombozi (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
If you need to have surgery or a procedure which may cause bleeding, your doctor might ask you to temporarily stop taking this medicine for a short while. 
Če imate predvideno operacijo ali poseg, ki lahko povzroči krvavitve, vam bo zdravnik morda svetoval, da začasno prenehate z jemanjem tega zdravila.
Eliquis has no or negligible influence on the ability to drive and use machines. 
Zdravilo Eliquis nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Table 5: Bleeding Results from Pivotal Phase III Studies* ADVANCE-3 
Preglednica 5: Rezultati spremljanja krvavitev iz ključnih študij III. faze* ADVANCE-3
The ADVANCE-3 study included 5,407 patients undergoing elective hip replacement, and the ADVANCE-2 study included 3,057 patients undergoing elective knee replacement. 
V študijo ADVANCE-3 je bilo vključenih 5.407 bolnikov, pri katerih je bila opravljena načrtovana kirurška zamenjava kolka, v študijo ADVANCE-2 pa 3.057 bolnikov pri katerih je bila opravljena načrtovana kirurška zamenjava kolena.
In the apixaban group, 342 patients received a loading dose (331 patients received the 10 mg dose and 11 patients received the 5 mg dose). 
V skupini z apiksabanom je polnilni odmerek prejelo 342 bolnikov (331 bolnikov je prejelo 10 mg odmerek, 11 bolnikov pa je prejelo 5 mg odmerek).
However, there is no clinical experience with the use of 4-factor PCC products to reverse bleeding in individuals who have received Eliquis. 
Vendar pa ni kliničnih izkušenj z uporabo 4-faktorskih pripravkov PCC za zaustavljanje krvavitev pri posameznikih, ki se zdravijo z zdravilom Eliquis.
The primary safety endpoint was major bleeding during the treatment period. 
Primarni opazovani dogodek pri vrednotenju varnosti je bila večja krvavitev v obdobju zdravljenja.
In the thrombin generation assay, apixaban reduced endogenous thrombin potential, a measure of thrombin generation in human plasma. 
V testu tvorbe trombina je apiksaban zmanjšal potencial endogenega trombina, kar je merilo tvorbe trombina v človeški plazmi.
AMPLIFY STUDY 
ŠTUDIJA AMPLIFY
The major observed effects in the repeated dose toxicity studies were those related to the pharmacodynamic action of apixaban on blood coagulation parameters. 
Večina opaženih učinkov pri študijah toksičnosti s ponavljajočimi se odmerki je bila povezana s farmakodinamičnim delovanjem apiksabana na parametre strjevanja krvi.
The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4). 
Trajanje zdravljenja se določi individualno po skrbni oceni koristi zdravljenja glede na tveganje za krvavitve (glejte poglavje 4.4).
Apixaban has multiple routes of elimination. 
Apiksaban se izloča po več poteh.
What you need to know before you take Eliquis 
Kaj morate vedeti, preden boste vzeli zdravilo Eliquis
See section 2 "Eliquis contains lactose (a type of sugar) and sodium". 
Glejte poglavje 2 ''Zdravilo Eliquis vsebuje laktozo (vrsta sladkorja) in natrij".
Your doctor will decide, if you should be treated with Eliquis when taking these medicines and how closely you should be monitored. 
Zdravnik bo presodil, če lahko zdravilo Eliquis jemljete skupaj z drugimi zdravili in kako pogosto vas bo med zdravljenjem treba nadzirati.
Based on patient medical history in the studied population of ADVANCE-3 and ADVANCE-2 (8,464 patients), 46% had hypertension, 10% had hyperlipidemia, 9% had diabetes, and 8% had coronary artery disease. 
Na osnovi zdravstvene anamneze je v raziskovani populaciji v študijah ADVANCE-3 in ADVANCE-2 (8.464 bolnikov) 46 % bolnikov imelo hipertenzijo, 10 % bolnikov hiperlipidemijo, 9 % bolnikov sladkorno bolezen in 8 % bolnikov bolezen koronarnih arterij.
Switching treatment from parenteral anticoagulants to Eliquis (and vice versa) can be done at the next scheduled dose (see section 4.5). 
Prehod s parenteralnega zdravljenja z antikoagulanti na zdravljenje z zdravilom Eliquis (in v obratni smeri) je mogoče opraviti ob naslednjem predvidenem odmerku (glejte poglavje 4.5).
However, since this may be due to a lower sensitivity of the non-clinical species compared to humans, this result should be interpreted with caution when extrapolating to humans. 
Ker so živalske vrste, uporabljene v predkliničnih študijah, morda manj občutljive v primerjavi s človekom, je treba vrednost teh rezultatov pri prenosu na človeka interpretirati previdno.
In patients undergoing hip replacement surgery The recommended duration of treatment is 32 to 38 days. 
Bolniki po kirurški zamenjavi kolka Priporočeno trajanje zdravljenja je od 32 do 38 dni.
Some medicines may increase the effects of Eliquis and some may decrease its effects. 
Nekatera zdravila lahko okrepijo, nekatera pa oslabijo učinek zdravila Eliquis.
The mean age was 56.9 years and 89.8% of randomised patients had unprovoked VTE events. 
Povprečna starost je bila 56,9 leta, 89,8 % randomiziranih bolnikov pa je imelo neizzvane dogodke VTE.
* Assessed by sequential testing strategy designed to control the overall type I error in the trial † Secondary endpoint. 
* ocenjeno s sekvenčno strategijo testiranja, ki je bila načrtovana za nadzor splošne napake tipa 1 v preskušanju † sekundarni opazovani dogodek
Activated charcoal Administration of activated charcoal reduces apixaban exposure (see section 4.9). 
Aktivno oglje Dajanje aktivnega oglja zmanjšuje izpostavljenost apiksabanu (glejte poglavje 4.9).
You should keep this card with you at all times. 
Kartico imejte ves čas pri sebi.
Discontinuing anticoagulants, including Eliquis, for active bleeding, elective surgery, or invasive procedures places patients at an increased risk of thrombosis. 
Ob prekinitvi uporabe antikoagulantov, vključno z zdravilom Eliquis, zaradi aktivne krvavitve, načrtovane operacije ali invazivnih postopkov, so bolniki izpostavljeni povečanemu tveganju za trombozo.
Please complete this section or ask your doctor to do it Name: 
Prosimo, izpolnite ta del ali prosite zdravnika, da ga izpolni.
What Eliquis is and what it is used for What you need to know before you take Eliquis How to take Eliquis 
Kaj je zdravilo Eliquis in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Eliquis Kako jemati zdravilo Eliquis Možni neželeni učinki
Apixaban also demonstrates anti-FXa activity as evident by reduction in Factor Xa enzyme activity in multiple commercial anti-FXa kits, however results differ across kits. 
Apiksaban kaže tudi aktivnost anti-FXa, kar je razvidno iz zmanjšanja encimske aktivnosti faktorja Xa pri številnih komercialno dostopnih testih anti-FXa, vendar pa se rezultati posameznih testov razlikujejo.
Cmin (ng/mL) 
apiksaban Cmin (ng/ml)
Eliquis should be restarted after the invasive procedure or surgical intervention as soon as possible provided the clinical situation allows and adequate haemostasis has been established (for cardioversion see section 4.2). 
Po invazivnem postopku ali kirurškem posegu je treba zdravljenje z zdravilom Eliquis čimprej ponovno začeti, pod pogojem, da klinična situacija to dovoljuje in da je bila vzpostavljena zadostna hemostaza (za kardioverzijo glejte poglavje 4.2).
Complete the following sections or ask your doctor to do it: 
Izpolnite ta del ali prosite zdravnika, da ga izpolni:
There are no data from the use of apixaban in pregnant women. 
Podatkov o uporabi apiksabana pri nosečnicah ni.
ASA was given at a once daily dose of 81 mg (64%), 162 (26.9%), 243 (2.1%), or 324 mg (6.6%) at the discretion of the investigator. 
Acetilsalicilno kislino so prejemali v enkratnem dnevnem odmerku, ki je po odločitvi raziskovalca znašal 81 mg (64 %), 162 (26,9 %), 243 (2,1 %), ali 324 mg (6,6 %).
• Guidance regarding switching from or to Eliquis treatment 
• navodila glede prehoda z zdravljenja ali na zdravljenje z zdravilom Eliquis
Both apixaban and enoxaparin were given for 32-38 days in the ADVANCE-3 study and for 10-14 days in the ADVANCE-2 study. 
V študiji ADVANCE-3 so bolniki apiksaban in enoksaparin prejemali od 32 do 38 dni, v študiji ADVANCE-2 pa od 10 do 14 dni.
Other medicines and Eliquis 
Druga zdravila in zdravilo Eliquis
If you are not sure whether a procedure may cause bleeding ask your doctor. 
Če niste prepričani, ali poseg lahko povzroči krvavitve, se posvetujte zzdravnikom.
The pharmacodynamic effects of apixaban are reflective of the mechanism of action (FXa inhibition). 
Farmakodinamični učinki apiksabana so odraz njegovega mehanizma delovanja (zaviranje faktorja Xa).
As with other anticoagulants, patients taking Eliquis are to be carefully observed for signs of bleeding. 
Kot pri drugih antikoagulantih je treba tudi bolnike, ki se zdravijo z zdravilom Eliquis, skrbno spremljati glede pojava znakov krvavitve.
For patients randomised to warfarin, the median percentage of time in therapeutic range (TTR) (INR 2-3) was 66%. 
Pri bolnikih, ki so bili randomizirani v skupino z varfarinom, je mediani odstotek časa v terapevtskem območju (TTR - Time in Therapeutic Range) (INR 2-3) znašal 66 %.
• symptomatic heart failure (NYHA Class ≥ II) 
• simptomatsko srčno popuščanje (razred ≥ II po NYHA)
Eliquis contains lactose (a type of sugar) and sodium 
Zdravilo Eliquis vsebuje laktozo (vrsta sladkorja) in natrij
The program was designed to demonstrate the efficacy and safety of apixaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and one or more additional risk factors, such as: 
Program je bil načrtovan z namenom, da bi dokazali učinkovitost in varnost uporabe apiksabana pri preprečevanju možganske kapi in sistemske embolije pri bolnikih z nevalvularno atrijsko fibrilacijo in enim ali več dodatnimi dejavniki tveganja, kot so na primer:
For patients not previously treated with anticoagulants, exclusion of left atrial thrombus using an image guided approach (e.g. transesophogeal echocardiography (TEE) or computed tomographic scan (CT)) prior to cardioversion should be considered, in accordance with established medical guidelines. 
Pri bolnikih, ki se predhodno niso zdravili z antikoagulanti, je treba pred kardioverzijo razmisliti o izključitvi strdka v levem atriju z uporabo pristopa na podlagi slikovne diagnostike (npr. transezofagealna ehokardiografija (TEE) ali slikanje z računalniško tomografijo (CT - Computed Tomography)), skladno z uveljavljenimi medicinskimi smernicami.
All 
Vse
Take special care with Eliquis - if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed. 
Bodite posebno pozorni pri jemanju zdravila Eliquis: če veste, da imate bolezen, imenovano antifosfolipidni sindrom (bolezen imunskega sistema, zaradi katere imate povečano tveganje za nastanek krvnih strdkov), o tem obvestite zdravnika, ki bo presodil, ali je treba zdravljenje spremeniti.
Apixaban is not a significant inhibitor of P-gp. 
Apiksaban ni pomemben zaviralec P-gp.
Preclinical studies of apixaban in animal models have demonstrated antithrombotic efficacy in the prevention of arterial and venous thrombosis at doses that preserved haemostasis. 
Predklinične študije na živalskih modelih so pokazale antitrombotično učinkovitost apiksabana pri preprečevanju arterijske in venske tromboze pri odmerkih, ki ohranijo hemostazo.
Patients were randomized 1:1 to apixaban or to heparin and/or VKA for the prevention of cardiovascular events. 
Bolnike so randomizirali 1 : 1 v skupino z apiksabanom ali v skupino s heparinom in/ali AVK za preprečevanje srčno-žilnih dogodkov.
Safety and efficacy of Eliquis have not been studied in patients with prosthetic heart valves, with or without atrial fibrillation. 
Varnosti in učinkovitosti zdravila Eliquis pri bolnikih s protetičnimi srčnimi zaklopkami z atrijsko fibrilacijo ali brez nje niso raziskovali.
After an operation to the hip or knee you may be at a higher risk of developing blood clots in your leg veins. 
Po operaciji kolka ali kolena se lahko poveča tveganje za razvoj krvnih strdkov v venah nog.
Apixaban is metabolised mainly via CYP3A4/5 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2. 
Apiksaban se v glavnem presnavlja preko CYP3A4/5 in le v manjši meri preko CYP1A2, 2C8, 2C9, 2C19 ter 2J2.
• Transfer all the powder carefully into a suitable container then mix the powder with a little e.g., 30 mL (2 tablespoons), water or one of the other liquids mentioned above to make a mixture. 
• Previdno prenesite ves prašek v primeren vsebnik in ga zmešajte z malo, npr. 30 ml (2 jedilni žlici), vode ali ene od drugih zgoraj naštetih tekočin, da dobite mešanico.
The adjudicated major bleeding and CRNM bleeding at any anatomical site were generally lower in the apixaban group as compared to the enoxaparin/warfarin group. 
Obravnavane večje krvavitve in klinično pomembne manjše krvavitve (KPMK) na kateremkoli anatomskem mestu so bile na splošno redkejše v skupini z apiksabanom v primerjavi s skupino z enoksaparinom/varfarinom.
In a clinical trial of patients with atrial fibrillation, concomitant use of ASA increased the major bleeding risk on apixaban from 1.8% per year to 3.4% per year and increased the bleeding risk on warfarin from 2.7% per year to 4.6% per year. 
V kliničnem preskušanju pri bolnikih z atrijsko fibrilacijo je sočasna uporaba acetilsalicilne kisline povečala tveganje za večje krvavitve ob uporabi apiksabana z 1,8 % na leto na 3,4 % na leto, tveganje za krvavitve ob uporabi varfarina pa z 2,7 % na leto na 4,6 % na leto.
Apixaban is a substrate of transport proteins, P-gp and breast cancer resistance protein (BCRP). 
Apiksaban je substrat za prenašalno beljakovino P-gp in rezistentno beljakovino, izolirano pri raku dojke (BCRP; “breast cancer resistance protein”).
Apixaban has no direct effects on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. 
Apiksaban nima neposrednega učinka na agregacijo trombocitov, vendar pa posredno zavira agregacijo trombocitov, ki jo povzroča trombin.
The mean age was 56.7 years and 91.7% of randomised patients had unprovoked VTE events. 
Povprečna starost je bila 56,7 leta, 91,7 % randomiziranih bolnikov pa je imelo neizzvane dogodke VTE.
Findings from a population pharmacokinetic analysis in patients who received apixaban were generally consistent with the phase I results. 
Ugotovitve analize populacijske farmakokinetike pri bolnikih, ki so se zdravili z apiksabanom, se na splošno skladajo z rezultati študij I. faze.
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from apixaban therapy. 
Odločiti se je treba med prenehanjem dojenja in prenehanjem/neuvedbo zdravljenja z apiksabanom.
Apixaban efficacy for prevention of a recurrence of a VTE was maintained across subgroups, including age, gender, BMI, and renal function. 
Učinkovitost apiksabana pri preprečevanju ponovne VTE je ostala nespremenjena v vseh podskupinah, glede na starost, spol, ITM in delovanje ledvic.
Common reasons for unsuitability for VKA therapy in the AVERROES study included unable/unlikely to obtain INRs at requested intervals (42.6%), patient refused treatment with VKA (37.4%), CHADS2 score = 1 and physician did not recommend VKA (21.3%), patient could not be relied on to adhere to VKA medicinal product instruction (15.0%), and difficulty/expected difficulty in contacting patient in case of urgent dose change (11.7%). 
Običajni vzroki za neprimernost zdravljenja z AVK v študiji AVERROES so bili naslednji: nezmožnost ali zelo majhna možnost za doseg vrednosti INR v zahtevanih območjih (42,6 %); bolniki so zavračali zdravljenje z AVK (37,4 %); ocena po merilih CHADS2 = 1, tako da zdravnik VKA ni priporočil (21,3 %); pri bolniku se ni bilo mogoče zanesti na to, da se bo držal navodil za zdravljenje z AVK (15,0 %); in težave oziroma pričakovane težave pri vzpostavljanju stika z bolnikom v primeru nujne spremembe odmerka (11,7 %).
In the toxicity studies little to no increase of bleeding tendency was found. 
V študijah toksičnosti niso zaznali povečanega nagnjenja k pojavu krvavitev ali pa je bilo nagnjenje le malenkostno večje.
In patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp the following recommendations apply (see section 4.5): 
Pri bolnikih, ki prejemajo sočasno sistemsko zdravljenje z močnimi induktorji tako CYP3A4 kot P-gp, veljajo naslednja priporočila (glejte poglavje 4.5):
If a dose is missed, the patient should take Eliquis immediately and then continue with twice daily intake as before. 
Če bolnik pozabi vzeti odmerek zdravila Eliquis, ga mora vzeti takoj ko se spomni, nato pa nadaljevati z jemanjem zdravila dvakrat na dan, kot pred tem.
If cardioversion is required before 5 doses of apixaban can be administered, a 10 mg loading dose should be given, followed by 5 mg twice daily. 
Če je kardioverzija potrebna, preden je mogoče dati 5 odmerkov apiksabana, je treba uporabiti 10 mg polnilni odmerek, čemur sledi 5 mg dvakrat na dan.
The pharmacokinetic /pharmacodynamic (PK/PD) relationship between apixaban plasma concentration and several PD endpoints (anti-FXa activity, INR, PT, aPTT) has been evaluated after administration of a wide range of doses (0.5 - 50 mg). 
Razmerje med farmakokinetiko/farmakodinamiko (PK/PD) med plazemskimi koncentracijami apiksabana in različnimi farmakodinamičnimi opazovanimi dogodki (aktivnost anti-FXa, INR, PČ, PTČ) so ovrednotili pri širokem razponu uporabljenih odmerkov (0,5 do 50 mg).
Always take this medicine exactly as your doctor or pharmacist has told you. 
Zdravilo jemljite redno, kot vam je naročil zdravnik.
Interaction with other medicinal products affecting haemostasis Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section 4.3). 
Interakcije z drugimi zdravili, ki vplivajo na hemostazo Zaradi povečanega tveganja za krvavitve je sočasno zdravljenje s katerimkoli drugim antikoagulantom kontraindicirano (glejte poglavje 4.3).
For patients randomised to warfarin, the mean percentage of time in therapeutic range (INR 2.0-3.0) was 60.9. 
Pri bolnikih, randomiziranih v skupino z varfarinom, je povprečen odstotek časa v terapevtskem območju (INR 2,0-3,0) znašal 60,9.
Inside the Eliquis pack together with the package leaflet you will find a Patient Alert Card or your doctor might give you a similar card. 
V škatlici zdravila Eliquis se skupaj z navodilom za uporabo nahaja opozorilna kartica za bolnika; podobno kartico vam bo morda dal tudi zdravnik.
If you miss a dose, take it as soon as you remember and continue to follow your dosing schedule. 
Če ste pozabili vzeti odmerek, tableto vzemite takoj, ko se spomnite, in nadaljujte z običajnim jemanjem zdravila.
In vitro apixaban studies showed no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 or CYP3A4 (IC50 > 45 µM) and weak inhibitory effect on the activity of CYP2C19 (IC50 > 20 µM) at concentrations that are significantly greater than peak plasma concentrations observed in patients. 
Pri in vitro študijah niso ugotovili zaviralnega učinka apiksabana na aktivnost CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 ali CYP3A4 (IC50 > 45 M) in šibek zaviralni učinek na aktivnost CYP2C19 (IC50 > 20 M) pri koncentracijah, ki so bile pomembno večje od največjih plazemskih koncentracij pri človeku.
Increases in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone. 
Povečanja vrednosti testov strjevanja krvi (PČ, INR in aPTČ) so bila skladna z učinki samostojno uporabljenega apiksabana.
The next dose of apixaban may be given at least 5 hours after catheter removal. 
Bolnik sme vzeti naslednji odmerek apiksabana najmanj 5 ur po odstranitvi katetra.
In patients with severe renal impairment (creatinine clearance 15-29 mL/min) the following recommendations apply (see sections 4.4 and 5.2): 
Pri bolnikih s hudo okvaro ledvic (očistek kreatinina 15-29 ml/min) veljajo naslednja priporočila (glejte poglavji 4.4 in 5.2):